comparemela.com
Home
Live Updates
Muvalaplin and Olpasiran Show Promise in Lowering Lp(a) : comparemela.com
Muvalaplin and Olpasiran Show Promise in Lowering Lp(a)
Oral muvalaplin lowered lipoprotein(a) in a phase 1 study, and injectable olpasiran did so in an extension of a phase 2 study, both with no adverse safety signals, researchers report.
Related Keywords
Boston ,
Massachusetts ,
United States ,
Amsterdam ,
Noord Holland ,
Netherlands ,
Australia ,
United Kingdom ,
Monash ,
South Australia ,
Melbourne ,
Victoria ,
American ,
Eli Lilly ,
Louise Bowman ,
Michellel Odonoghue ,
Stephenj Nicholls ,
University Of Oxford ,
European Society Of Cardiology ,
Harvard Medical School ,
Amgen ,
Medicines Company ,
American Heart Association Scientific Sessions ,
Monash University ,
Astrazeneca ,
Victoria Heart Institute ,
Boehringer Ingelheim ,
Novartis ,
European Society ,
New England Journal ,
New Amsterdam Pharma ,
Lipids ,
Ipid Management ,
Cv ,
Ardiovascular ,
Pcsk9 ,
Roprotein Convertase Subtilisin Kexin Type 9 ,
Grant ,
Heart ,
Low Ldl Cholesterol ,
Ypobetalipoproteinemia ,
Ow Low Density Lipoprotein Cholesterol ,
Apolipoproteins ,
Atherosclerosis ,
Body Mass Index Bmi ,
Cardiovascular Disease ,
Vd Cardiovascular Disease ,
Fatigue ,
Genetics ,
Hospitals ,
Imbalance ,
Interference ,
Lipoproteins ,
Liver ,
Genomi ,
comparemela.com © 2020. All Rights Reserved.